

Characteristic	no.—(%)
Patients (n=48) Sex no.—(%)	
Male	32 (66.7)
Female	16 (33.3)
Age – years, no. (%)	
< 65	22 (45.8)
≥ 65	36 (54.2)
Range	24-96
Mean (SD)	64, (+/- 18.8)
Median [IQR]	67, [54.3-77.3]
Symptom Onset – days	
Range	2-7
Mean, (SD)	3.8, (+/-1.8)
Median, (IQR)	3, [2-5]
Fever (≥ 37.8°C) no. (%)	
Yes	41 (85.4)
No	7 (14.6)
Final Disposition no. (%)	
Home	15 (31.3)
In-patient	32 (66.7)
Died	1 (2.1)
Final Diagnosis no. (%)	
COVID/Viral	35 (72.9)
Non-COVID	1 (2.1)
Bacterial	8 (16.7)
Non-Infectious	4 (8.3)
FebriDx Results no. (%)	
Viral	35 (72.9)
Bacterial	11 (22.9)
Non-Infectious	2 (4.2)
Procalcitonin (ng/mL)	
Range	0.05-13.4
Median, [IQR]	0.17, [0.08-0.33]
C-Reactive Protein (mg/L)	
Range	5-310
Median, [IQR]	74, [38.0-113.5]
Leukocyte Count	
Range	2.6-19.1
Median, [IQR]	9.1, [5.3-11.1]
Lymphocyte Count	
Range	0.04-8.4
Median, [IQR]	0.95, [0.7-1.4]

**Table 1.** Cohort Characteristics

	Sensitivity	Specificity	PPV	NPV
FeбриDx COVID-19 Only	100%	100%	100%	100%
FeбриDx Viral Infection (all)	97.2%	100%	100%	92.3%
FeбриDx Bacterial Infection	100%	92.5%	72.7%	100%
rRT-PCR COVID-19 Only	85.7%	100%	100%	72.2%

**Table 2.** PPV and NPV of FeбриDx and rRT-PCR in the cohort

*PPV, positive predictive value; rRT-PCR, reverse transcriptase polymerase chain reaction; NPV, negative predictive value*

Viral Diagnostic Performance (COVID-19) (FebriDx vs. Clinical Truth)				Bacterial Diagnostic Performance (FebriDx vs. Clinical Truth)			
	Clinical Truth			Clinical Truth			
	+	-	Total	+	-	Total	
+	35	0	35	8	3	11	
-	0	13	13	0	37	37	
Total	35	13	48	8	40	48	
Sensitivity	100.0%	TP/TP+FN		100.0%	TP/TP+FN		
Specificity	100.0%	TN/FP+FN		92.5%	TN/FP+FN		
NPV	100.0%	TN/FN+TN		100.0%	TN/FN+TN		
PPV	100.0%	TP/TP+FP		72.7%	TP/TP+FP		

  

Viral Diagnostic Performance (COVID-19 + non COVID viral infections) (FebriDx vs. Clinical Truth)				Viral Diagnostic Performance (COVID-19) (PCR vs. Clinical Truth)			
	Clinical Truth			Clinical Truth			
	+	-	Total	+	-	Total	
+	35	0	35	30	0	30	
-	1	12	13	5	13	18	
Total	36	12	48	35	13	48	
Sensitivity	97.2%	TP/TP+FN		85.7%	TP/TP+FN		
Specificity	100.0%	TN/FP+FN		100.0%	TN/FP+FN		
NPV	92.3%	TN/FN+TN		72.2%	TN/FN+TN		
PPV	100.0%	TP/TP+FP		100.0%	TP/TP+FP		

**Table 3.** Diagnostic performance of FebriDx in COVID-19, non-COVID and bacterial

infections, compared to rRT-PCR and clinical suspicion for COVID-19

*PPV, positive predictive value; rRT-PCR, reverse transcriptase polymerase chain*

*reaction; NPV, negative predictive value*